Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of telisotuzumab vedotin dosing regimens in previously treated c-Met overexpressing non-squamous NSCLC
MOH_2024-09-03_013621Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab vedotin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AbbVie Inc. Started Oct 2024; status: recruiting.
02
Drugs
telisotuzumab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2024-09-03_013621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-03_013621.